Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia

International Journal of Clinical Practice

Volumn 60, Issue 8, 2006, Pages 914-921

  Patel, Jeteesh V ^a   Hughes, E A ^a  

^a SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Coronary heart disease; Ezetimibe; Simvastatin

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BREAST DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART MUSCLE FIBROSIS; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK REDUCTION; SKIN DISEASE; SUDDEN DEATH; THORAX DISEASE; THORAX PAIN; UNITED KINGDOM; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33746168981     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01023.x     Document Type: Article

References (15)

1. MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
2. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
3. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events: NICE technology appraisal 94 http://www.nice.org.uk/TAO94
4. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
5. Pedersen TR, Faergeman O, Kastelein JJ et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study, a randomized controlled trial. J Am Med Assoc 2005; 294: 2437-45.
6. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
7. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
8. Patel JV, Kirby M, Hughes EA. The Lipid Audit: Analysis of lipid management in two centres in Britain 2003. Br J Cardiol 2004; 11: 214-7.
9. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
10. Joint British Societies. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl. 5): V1-52.
11. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: Position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21: 959-69.
12. Dujovne C, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1092-7.
13. Davidson M, McGarry T, Bettis R et al. for the Ezetimibe Study Group. Ezetimibe co administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-34.
14. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-73.
15. Brewer HB. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92: 23K-9K.